Clinical trial
Clinical Trial of HuMax-CD4, a New Drug to Treat Early Stage T-Cell Lymphoma in…
NCT00071071 · Genmab, Industry · Completed
Key facts
| NCT number | NCT00071071 |
|---|---|
| Title | Clinical Trial of HuMax-CD4, a New Drug to Treat Early Stage T-Cell Lymphoma in the Skin. |
| Official title | An Open-Label Therapeutic Exploratory Clinical Trial of HuMax-CD4, a Fully Human Monoclonal Anti-CD4 Antibody, in Patients With Refractory or Persistent Early Stage (IA-IIA) Cutaneous T-Cell Lymphoma |
| Lead sponsor | Genmab, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cutaneous T-Cell Lymphoma |
| Intervention type | Drug |
| Interventions | HuMax-CD4 |
| Enrollment | 25 |
| Start date | Apr 30, 2003 |
| Primary completion | May 5, 2004 |
| Completion | May 5, 2004 |
| First posted | Oct 15, 2003 |
| Last update posted | May 18, 2023 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: